Search

Ionis Pharmaceuticals Inc

Fermé

SecteurSoins de santé

56.71 -2.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

57.73

Max

58.26

Chiffres clés

By Trading Economics

Revenu

-22M

-115M

Ventes

22M

268M

BPA

-0.7

Marge bénéficiaire

-42.787

Employés

1,480

EBITDA

-37M

-105M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+52.73% upside

Dividendes

By Acuity

Prochains Résultats

28 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

783M

10B

Ouverture précédente

58.93

Clôture précédente

56.71

Sentiment de l'Actualité

By Acuity

50%

50%

134 / 339 Classement par Healthcare

Ionis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 sept. 2026, 00:05 UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

4 sept. 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

3 sept. 2026, 22:02 UTC

News

Ionis Pharmaceuticals shares are higher in after-hours trading following FDA approval for Zanvastro, the first treatment for Alexander disease.

2 sept. 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting notable selling pressure since Wednesday's close. No specific news was identified to explain the decline.

1 sept. 2026, 22:01 UTC

Ionis Pharmaceuticals Inc shares are trading higher in after-market hours, reversing a trend of five consecutive lower sessions. No specific news was identified.

31 août 2026, 19:56 UTC

News

Ionis Pharmaceuticals shares are lower today following negative results from a failed trial of Wainua, which did not meet its primary endpoint.

28 août 2026, 21:01 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines despite remaining above the 20-day moving average.

27 août 2026, 23:46 UTC

Ionis Pharmaceuticals shares traded near unchanged during after-market hours, reflecting routine activity. The stock has declined for three consecutive sessions.

26 août 2026, 23:51 UTC

Ionis Pharmaceuticals is rising in after-market hours, reflecting broader market gains amid positive economic data on durable goods orders and inflation indicators.

25 août 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, maintaining momentum above the 20-day moving average amid a broader market reaction to falling crude oil prices.

24 août 2026, 23:11 UTC

Ionis Pharmaceuticals shares are higher in after-market hours following a session low. Broader market performance remains subdued amid ongoing geopolitical concerns.

22 août 2026, 00:01 UTC

Ionis Pharmaceuticals Inc is higher in after-market trading, reflecting strength amid a broader market rebound. The stock remains above its 20-day moving average.

21 août 2026, 22:51 UTC

Ionis Pharmaceuticals Inc shares are trading higher during after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

20 août 2026, 20:02 UTC

News
Event

Ionis Pharmaceuticals will present new data on hypertriglyceridemia treatments at the European Society of Cardiology Congress, though shares are trading lower today.

19 août 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

18 août 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.

17 août 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14 août 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13 août 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12 août 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11 août 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10 août 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7 août 2026, 20:03 UTC

News

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.

6 août 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5 août 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4 août 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3 août 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1 août 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31 juil. 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30 juil. 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

Comparaison

Variation de prix

Ionis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

52.73% hausse

Prévisions sur 12 Mois

Moyen 88.72 USD  52.73%

Haut 115 USD

Bas 61 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

16

Achat

4

Maintien

0

Vente

Sentiment

By Acuity

134 / 339Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat